Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–82 of 82 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Remodulin Clear all

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: Tucson, Arizona • San Francisco, California • Torrance, California

Conditions: Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Jacksonville, Florida • Weston, Florida

Conditions: Pulmonary Arterial Hypertension
Interventions: inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 1,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 88
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil diethanolamine; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Inhaled treprostinil solution, Placebo solution; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Critical Limb Ischemia
Interventions: UT-15C SR (treprostinil diethanolamine) 1mg oral tablets; Drug
Lead sponsor: Southern Arizona Vascular Institute; Other
Eligibility: 45 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Tucson, Arizona • Springfield, Illinois

Conditions: Pulmonary Hypertension
Interventions: Oral treprostinil (UT-15C) sustained release tablets, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Systemic Sclerosis, Scleroderma
Interventions: treprostinil diethanolamine, placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 24
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 21 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Inhalation Powder; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 12 more

Conditions: Pulmonary Hypertension
Interventions: UT-15C SR, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 33 more

Search by objective public record fields.

Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

UT-15C SR in the Treatment of Critical Limb Ischemia

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension